FDA Sets July 23–24 Meeting to Review BPC-157, TB-500, and 5 More Peptides for Compounding Access

On April 15, 2026, the FDA published a Federal Register notice announcing that the Pharmacy Compounding Advisory Committee will meet on July 23–24, 2026 to evaluate seven peptide compounds for potential inclusion on the Section 503A bulk drug substances list. The meeting will be held at the FDA White Oak Campus in Silver Spring, Maryland, with remote participation available.

This is a major escalation from HHS Secretary Robert F. Kennedy Jr.'s February 2026 announcement that 14 of 19 restricted peptides would return to Category 1 status. That announcement signaled policy intent — this meeting is the formal regulatory mechanism to execute it. The advisory committee will vote on whether each peptide meets the criteria for inclusion on the compounding list, and the FDA will consider those recommendations when making its final determination.

The FDA simultaneously established a public comment docket (FDA-2025-N-6895) that will remain open until July 22, 2026. Comments submitted by July 9 will be provided directly to the committee before the meeting. The agency is accepting written comments, clinical data, safety information, and patient experience reports related to the seven peptides under review.

The first day of the meeting will review four peptide categories, each in both free base and acetate salt forms. These are the peptides with the broadest patient use history and the largest compounding market prior to the 2023 restrictions.

BPC-157 (Body Protection Compound-157) is the single most widely compounded peptide and the most commercially significant substance on the agenda. Before the ban, BPC-157 was primarily prescribed for gastrointestinal conditions, tendon and ligament injuries, and general tissue repair. The FDA will evaluate it specifically for ulcerative colitis as the nominated indication. The committee will review the existing preclinical literature (over 100 animal studies) alongside the notably thin human clinical evidence — a gap that critics argue should preclude compounding access and proponents argue has been filled by decades of clinical observation.

TB-500 (Thymosin Beta-4 fragment) was one of the most commonly used regenerative peptides alongside BPC-157. The FDA will evaluate it for wound healing applications. TB-500 carries additional scrutiny due to published concerns about its potential effects on cell proliferation and angiogenesis, which some researchers have flagged as a theoretical cancer-related risk. This was the primary reason TB-500 was expected to remain restricted under the initial RFK Jr. reclassification announcement in February — its inclusion on the July agenda suggests those concerns are being formally reconsidered.

KPV (Lysine-Proline-Valine tripeptide) is an anti-inflammatory peptide derived from alpha-melanocyte-stimulating hormone. It will be evaluated for wound healing and inflammatory conditions. KPV has a smaller clinical use footprint than BPC-157 or TB-500, but has been increasingly prescribed by integrative medicine practitioners for gut inflammation and dermatological conditions.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a mitochondrial-derived peptide that will be evaluated for obesity and osteoporosis. MOTS-c is among the newer peptides to gain clinical traction and has attracted research interest for its role in metabolic regulation, insulin sensitivity, and exercise mimetic effects.

The second day will review three peptides with more specialized therapeutic niches. Each will be evaluated in both free base and acetate forms.

Emideltide (Delta Sleep-Inducing Peptide / DSIP) is a neuropeptide originally identified in rabbit brain tissue in 1977. It has been used in integrative medicine for sleep disorders and stress-related insomnia. While the name implies a straightforward sleep function, the actual mechanism is more complex — DSIP appears to modulate neuroendocrine signaling and may affect cortisol regulation and pain perception in addition to sleep architecture. The clinical evidence base is limited but includes several small European clinical studies from the 1980s and 1990s.

Semax is a synthetic analog of adrenocorticotropic hormone (ACTH 4-10) originally developed in Russia. It has been used for cognitive enhancement, neuroprotection, and anxiety. Semax has a more robust clinical history than many peptides on this list — it was approved as a pharmaceutical product in Russia (brand name Semax) and has been the subject of multiple clinical studies, though few meet Western regulatory standards for trial design and reporting. The committee will need to weigh this international clinical history against the FDA's domestic evidence requirements.

Epitalon (Epithalon / Epithalone) is a synthetic tetrapeptide studied for its effects on telomerase activation and potential anti-aging properties. It was developed by Russian gerontologist Vladimir Khavinson and has been the subject of both animal and limited human research related to telomere biology and immune function. Epitalon occupies a unique position on the agenda — its primary use case (longevity and anti-aging) falls outside traditional disease-treatment frameworks, which may complicate the committee's evaluation under standard safety and efficacy criteria.

The FDA is actively soliciting public input on the seven peptides under review. This is a meaningful opportunity for patients, physicians, researchers, and compounding pharmacies to contribute evidence and perspectives to the committee's deliberations.

Docket number: FDA-2025-N-6895. All submissions must reference this docket number.

Electronic submissions: Comments can be submitted online at regulations.gov by searching for the docket number. The electronic filing system accepts comments until 11:59 PM Eastern Time on July 22, 2026.

Deadline for committee review: While the docket remains open through July 22, comments submitted by July 9, 2026 will be compiled and provided directly to the advisory committee members before the meeting. Comments submitted after July 9 but before July 22 will still be part of the public record but may not be reviewed by committee members prior to their vote.

What to include: The FDA's Federal Register notice indicates the committee is interested in data, information, and views related to the nominated peptides. If you are a patient who used one of these peptides before the ban, documenting your clinical experience — including the prescribing context, outcomes, and any adverse effects — provides the kind of real-world evidence that can inform the committee's evaluation. Physicians can submit clinical observations, case series data, and professional assessments of the benefit-risk profile. Researchers can submit published or unpublished data relevant to safety, efficacy, or manufacturing quality.

Oral presentations: Individuals who wish to make oral presentations at the meeting should notify the FDA contact person listed in the Federal Register notice. Time for public presentations will be allocated during the meeting, and speakers will typically have 3–5 minutes.

This advisory committee meeting does not exist in a regulatory vacuum. It is the direct result of sustained political pressure from HHS Secretary Robert F. Kennedy Jr. and the broader Make America Healthy Again (MAHA) movement.

Kennedy has been the most prominent government official to publicly advocate for peptide access. In a widely cited interview with podcaster Joe Rogan, Kennedy stated that he is "a big fan of peptides" and that he has "used them myself and with really good effect on a couple of injuries." He argued that the FDA under the Biden administration had "illegally moved" these peptides onto the restricted list, a characterization the FDA disputes.

Kennedy's February 2026 announcement that 14 of 19 restricted peptides would return to Category 1 framed the reclassification as restoring patient choice and physician autonomy. The July advisory committee meeting is the formal process to execute that policy shift — the committee's recommendations will carry significant weight, though the FDA Commissioner retains final authority on list changes.

The political dimension creates a complex dynamic. Supporters argue that career FDA regulators had overstepped by restricting compounds with decades of clinical use and that the advisory committee process restores proper scientific review. Critics, including former FDA officials, contend that the process is being driven by political pressure rather than new safety data. Dr. Peter Lurie, former FDA associate commissioner and current president of the Center for Science in the Public Interest, has warned that allowing peptides without adequate clinical data represents a fundamental threat to the FDA's drug evaluation framework.

For patients and physicians, the political context is less important than the practical outcome. Regardless of the political motivations, the advisory committee will evaluate each peptide on its scientific merits — and those recommendations will determine whether legal compounding access is restored.

The fundamental tension in this review is the gap between widespread clinical use and formal evidence. Here is a summary of the evidence landscape for each peptide on the July agenda.

BPC-157 has the largest preclinical evidence base of any peptide under review — over 100 published animal studies demonstrating tissue-protective and healing effects across gastrointestinal, musculoskeletal, and neurological models. However, controlled human clinical trials are essentially absent. A 2024 systematic review in orthopaedic sports medicine found 35 preclinical studies but only one small retrospective human series with no randomized controlled trials. Proponents point to decades of clinical use and thousands of patient reports; critics argue that animal data — no matter how extensive — cannot substitute for controlled human studies.

TB-500 has moderate preclinical evidence for wound healing and tissue repair, but carries the additional complexity of theoretical concerns about angiogenesis and cell proliferation. The evidence for and against a cancer-related risk is inconclusive, which means the committee will need to evaluate an ambiguous safety signal — a difficult task without human data to resolve the question.

KPV has a smaller but growing evidence base, primarily in vitro and animal studies demonstrating anti-inflammatory effects. Human clinical evidence is minimal. Its mechanism is well-characterized (alpha-MSH-derived anti-inflammatory signaling), which may support a mechanistic argument for safety even in the absence of clinical trials.

MOTS-c has generated significant research interest as a mitochondrial-derived peptide with metabolic effects. Published studies include both preclinical and early clinical data, with a 2024 study demonstrating effects on insulin sensitivity in humans. The committee may find more to work with here than for some other peptides on the list.

Emideltide (DSIP) has an older evidence base, primarily from European clinical research in the 1980s–1990s, which presents methodological challenges by modern standards. The committee will need to decide how much weight to give these historical studies.

Semax has the strongest clinical pedigree of any peptide on the July agenda, with pharmaceutical approval in Russia and multiple clinical studies — though many do not meet current Western trial design standards. The cross-jurisdictional evidence question will be interesting to watch.

Epitalon has limited clinical evidence, primarily from studies by its developer. The longevity use case adds complexity because the FDA's evaluation framework is designed around disease treatment, not aging prevention.

The advisory committee's recommendations are not self-executing. Here is the process that follows the July 23–24 meeting.

Committee votes: At the end of each peptide's review session, the committee will vote on whether to recommend inclusion on the 503A bulk drug substances list. These votes are advisory — they represent the committee's scientific judgment but do not automatically change policy.

FDA review: The FDA will consider the committee's recommendations alongside the public comments, its own internal review, and any additional data or analysis. The FDA Commissioner has the authority to accept, modify, or reject advisory committee recommendations, though FDA typically follows committee votes — historically, the agency follows advisory committee recommendations roughly 75–80% of the time.

Federal Register publication: If the FDA decides to add peptides to the 503A list, the change will be published in the Federal Register. Until that publication occurs, the legal status remains unchanged. Compounding pharmacies should not begin compounding any of these peptides until the Federal Register notice is published.

Timeline uncertainty: The FDA has not specified how long the post-meeting review process will take. Based on precedent with other advisory committee actions, a decision could come weeks to months after the meeting. Patients and practitioners should plan for uncertainty and avoid assuming a specific timeline.

Future meetings: The FDA has indicated that additional peptides from the original 19 restricted substances will be reviewed at a separate meeting, the date for which has not yet been announced. The phased approach suggests the agency is handling the review methodically rather than as a single blanket reclassification.

If you are a patient who used one of these peptides before the 2023 restrictions, or if you are considering peptide therapy pending the outcome of this review, here is practical guidance.

Do not purchase from unregulated sources. The peptides under review are not currently legal to compound. Purchasing from gray-market websites or overseas suppliers carries significant risks — contamination, mislabeling, and counterfeit products are well-documented in the unregulated peptide market. The Eli Lilly counterfeit tirzepatide warning earlier this year underscores the real dangers of unregulated supply chains. Wait for the formal regulatory outcome.

Submit a public comment if you have relevant experience. If you used BPC-157, TB-500, Semax, or any of the other peptides under review and have a documented clinical experience (positive or negative), your input is directly relevant to the committee's work. Use docket FDA-2025-N-6895 at regulations.gov and submit by July 9 for committee review.

Talk to your physician. If you are currently seeking peptide therapy, discuss FDA-approved alternatives with your prescribing physician. For some indications — particularly weight management, growth hormone deficiency, and certain immune conditions — FDA-approved options with established safety profiles exist.

Follow the meeting. The July 23–24 meeting will include remote participation. Watching the committee's discussion will give you real-time insight into how the scientific evaluation is proceeding and what safety concerns or evidence gaps the committee identifies.

Manage expectations. A positive advisory committee vote does not mean immediate access. The FDA's post-meeting review, Federal Register publication, and pharmacy preparation timelines mean that even an optimistic scenario involves weeks to months between the meeting and actual availability of legally compounded peptides. Plan accordingly and avoid making treatment decisions based on anticipated regulatory outcomes.